Cargando…

Frequency and Effectiveness of Empirical Anti-TNF Dose Intensification in Inflammatory Bowel Disease: Systematic Review with Meta-Analysis

Loss of response to antitumor necrosis factor (anti-TNF) therapies in inflammatory bowel disease occurs in a high proportion of patients. Our aim was to evaluate the loss of response to anti-TNF therapy, considered as the need for dose intensification (DI), DI effectiveness and the possible variable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guberna, Laura, Nyssen, Olga P., Chaparro, María, Gisbert, Javier P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8156358/ https://www.ncbi.nlm.nih.gov/pubmed/34069295 http://dx.doi.org/10.3390/jcm10102132

Ejemplares similares

Primary Failure to an Anti-TNF Agent in Inflammatory Bowel Disease: Switch (to a Second Anti-TNF Agent) or Swap (for Another Mechanism of Action)?
por: Gisbert, Javier P., et al.
Publicado: (2021)

Empirical vs. Susceptibility-Guided Treatment of Helicobacter pylori Infection: A Systematic Review and Meta-Analysis
por: Nyssen, Olga P., et al.
Publicado: (2022)

Systematic review and meta-analysis: evaluating response to empiric anti-TNF dose intensification for secondary loss of response in Crohn’s disease
por: Srinivasan, Ashish, et al.
Publicado: (2022)

Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn’s Disease
por: Gisbert, Javier P., et al.
Publicado: (2023)

Metabolomics Insights into Inflammatory Bowel Disease: A Comprehensive Review
por: Aldars-García, Laila, et al.
Publicado: (2021)

Systematic Review: Urine Biomarker Discovery for Inflammatory Bowel Disease Diagnosis
por: Baldan-Martin, Montse, et al.
Publicado: (2023)

Differential Effects of Anti-TNFα and Anti-α4β7 Drugs on Circulating Dendritic Cells Migratory Capacity in Inflammatory Bowel Disease
por: Soleto, Irene, et al.
Publicado: (2022)

Systematic Review: The Gut Microbiome and Its Potential Clinical Application in Inflammatory Bowel Disease
por: Aldars-García, Laila, et al.
Publicado: (2021)

Gut Microbiota and Dietary Factors as Modulators of the Mucus Layer in Inflammatory Bowel Disease
por: Fernández-Tomé, Samuel, et al.
Publicado: (2021)

Anti-TNF Withdrawal in Inflammatory Bowel Disease
por: Torres, Joana, et al.
Publicado: (2016)

The Interplay between Immune System and Microbiota in Inflammatory Bowel Disease: A Narrative Review
por: Aldars-García, Laila, et al.
Publicado: (2021)

Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseases
por: Gonczi, Lorant, et al.
Publicado: (2017)

Anti‐TNF‐induced lupus in patients with inflammatory bowel disease
por: Picardo, Sherman, et al.
Publicado: (2019)

Effects of Golimumab and Ustekinumab on Circulating Dendritic Cell Migratory Capacity in Inflammatory Bowel Disease
por: Soleto, Irene, et al.
Publicado: (2023)

Articular manifestations in patients with inflammatory bowel diseases treated with anti-TNF
por: Cachen, Laurie, et al.
Publicado: (2022)

Anti-tumour necrosis factor discontinuation in inflammatory bowel disease patients in remission: study protocol of a prospective, multicentre, randomized clinical trial
por: Chaparro, María, et al.
Publicado: (2019)

Impact of comorbidities on anti-TNFα response and relapse in patients with inflammatory bowel disease: the VERNE study
por: Marin-Jimenez, Ignacio, et al.
Publicado: (2020)

A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease
por: Aardoom, Martine A., et al.
Publicado: (2019)

Pott’s Puffy Tumor in an Inflammatory Bowel Disease Patient on Anti-TNF Therapy
por: Miri, Ahmad, et al.
Publicado: (2021)

Recent Advances in the Optimization of Anti-TNF Treatment in Patients with Inflammatory Bowel Disease
por: Orfanoudaki, Eleni, et al.
Publicado: (2023)

Evaluation of the Effectiveness of Helicobacter pylori Eradication Regimens in Lithuania during the Years 2013–2020: Data from the European Registry on Helicobacter pylori Management (Hp-EuReg)
por: Jonaitis, Paulius, et al.
Publicado: (2021)

Empirical or susceptibility-guided treatment for Helicobacter pylori infection? A comprehensive review
por: Gisbert, Javier P.
Publicado: (2020)

Loss of response to anti‐TNFα agents depends on treatment duration in patients with inflammatory bowel disease
por: Schultheiss, Johannes P. D., et al.
Publicado: (2021)

The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU
por: Chaparro, María, et al.
Publicado: (2021)

A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy
por: Chebli, Júlio Maria Fonseca, et al.
Publicado: (2014)

IgA Nephropathy in the Setting of Anti-TNF-α Therapy for Inflammatory Bowel Disease
por: Strobel, Thomas, et al.
Publicado: (2020)

Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2020)

Whole Transcription Profile of Responders to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
por: Salvador-Martín, Sara, et al.
Publicado: (2021)

Investigation of the effects of anti-TNF agents on hemoglobin levels in patients with inflammatory bowel disease
por: Okuyucu, Muhammed, et al.
Publicado: (2022)

10 years of biologic use patterns in patients with inflammatory bowel disease: treatment persistence, switching and dose intensification – a nationwide population-based study
por: Koo, Hee Moon, et al.
Publicado: (2023)

Clinical and laboratory markers associated with anti-TNF-alpha trough levels and anti-drug antibodies in patients with inflammatory bowel diseases
por: Grinman, Ana B., et al.
Publicado: (2020)

Relapse after withdrawal from anti‐TNF therapy for inflammatory bowel disease: an observational study, plus systematic review and meta‐analysis
por: Kennedy, N. A., et al.
Publicado: (2016)

Cost-Effectiveness of Therapeutic Drug Monitoring of Anti-TNF Therapy in Inflammatory Bowel Disease: A Systematic Review
por: Marquez-Megias, Silvia, et al.
Publicado: (2022)

Changes in Anthropometric Parameters After Anti-TNFα Therapy in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis
por: Mazhar, Faizan, et al.
Publicado: (2020)

Systematic review and meta-analysis: real-world data rates of deep remission with anti-TNFα in inflammatory bowel disease
por: Alipour, Omeed, et al.
Publicado: (2021)

Is the Therapeutic Drug Monitoring of Anti-TNF Agents Necessary in Korean Inflammatory Bowel Disease Patients?
por: Eun, Chang Soo
Publicado: (2017)

Systematic review: genetic biomarkers associated with anti‐TNF treatment response in inflammatory bowel diseases
por: Bek, S., et al.
Publicado: (2016)

Anti-TNF-α Therapy Suppresses Proinflammatory Activities of Mucosal Neutrophils in Inflammatory Bowel Disease
por: Zhang, Cui, et al.
Publicado: (2018)

Potential Impact of Diet on Treatment Effect from Anti-TNF Drugs in Inflammatory Bowel Disease
por: Andersen, Vibeke, et al.
Publicado: (2017)

Risk of Lymphoma Associated with Anti-TNF Therapy in Patients with Inflammatory Bowel Disease: Implications for Therapy
por: Dahmus, Jessica, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_omavrr4q378djidprsvsv8u2c1